Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2385654
Main Authors: Fu, Quanlan, Luo, Yuandong, Li, Junjie, Zhang, Pingping, Tang, Shuxian, Song, Xinyi, Fu, Jiawei, Liu, Mengqi, Mo, Rongmi, Wei, Ming, Li, Hejie, Liu, Xiaosong, Wang, Tianfang, Ni, Guoying
Format: Article
Language:English
Subjects:
Animals
Antimicrobial Cationic Peptides - immunology
Antimicrobial Cationic Peptides - therapeutic use
Caerin 1 peptide
Humans
immune checkpoint blockade
Immunotherapy - methods
macrophage
Neoplasms - immunology
Neoplasms - therapy
Peptides - immunology
Peptides - therapeutic use
therapeutic vaccine
tumor microenvironment
Tumor Microenvironment - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer remains a major global health challenge. Immunotherapy has revolutionized the management of cancer, yet only a limited number of patients respond to such treatments. This is largely attributed to the immunosuppressive tumor microenvironment, which diminishes the effectiveness of immunotherapy. Recent studies have underscored the potential of naturally derived caerin 1 peptides, particularly caerin 1.1 and caerin 1.9, which exhibit strong antitumor effects and enhance the efficacy of immunotherapies in animal models. This review encapsulates the current research aimed at augmenting the effectiveness of immunotherapy, focusing on the role of caerin 1.1 and caerin 1.9 in boosting immunotherapeutic outcomes, elucidating possible mechanisms, and discussing their limitations and challenges.
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2024.2385654